


#### PHARMACEUTICAL 2017

**REVANCE**°

# Revance Therapeutics Inc. Rank 70 of 292





### PHARMACEUTICAL 2017

#### **REVANCE**



## Revance Therapeutics Inc. Rank 70 of 292

The relative strengths and weaknesses of Revance Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Revance Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 108% points. The greatest weakness of Revance Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 186%, being 183% points above the market average of 2.9%.

| Input Variable                              | Value in<br>1000 USD |
|---|----------------------|
| Assets, Current                             | 192,695              |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 0                    |
| Liabilities, Current                        | 19,647               |
| Liabilities, Non-Current                    | 100                  |
| Other Assets                                | 1,080                |
| Other Compr. Net Income                     | -5.0                 |
| Other Expenses                              | 10,141               |
| Other Liabilities                           | 7,542                |
| Other Net Income                            | 27                   |
| Other Revenues                              | 300                  |
| Property and Equipment                      | 10,585               |
| Research and Development                    | 50,381               |
| Selling, General and Administrative Expense | 29,075               |

| Output Variable          | Value in<br>1000 USD |
|--------------------------|----------------------|
| Assets                   | 204,360              |
| Liabilities              | 27,289               |
| Expenses                 | 89,597               |
| Revenues                 | 300                  |
| Stockholders Equity      | 177,071              |
| Net Income               | -89,270              |
| Comprehensive Net Income | -89,272              |
| Economic Capital Ratio   | 186%                 |

